Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.

Bing-Ying Xu, Li-Ping Guo, Shui-Shan Lee, Qing-Ming Dong, Yi Tan, Hong Yao, Li-Hua Li, Che-Kit Lin, Hsiang-Fu Kung, Ming-Liang He, Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World Journal of Gastroenterology. ,vol. 13, pp. 2100- 2103 ,(2007) , 10.3748/WJG.V13.I14.2100

C Orkin, ST Sadiq, L Rice, F Jackson, , Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects Hiv Medicine. ,vol. 11, pp. 187- 192 ,(2010) , 10.1111/J.1468-1293.2009.00762.X

Jennifer King, Judith A Aberg, Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS. ,vol. 22, pp. 1709- 1717 ,(2008) , 10.1097/QAD.0B013E32830163AD

Kin Wang To, Shui Teng Liu, Siu Wai Cheung, D Pui Chung Chan, R Chiu Yeung Chan, Shui Shan Lee, Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Therapeutic Drug Monitoring. ,vol. 31, pp. 527- 530 ,(2009) , 10.1097/FTD.0B013E3181AD74A4

Hsin-Yun Sun, Chien-Ching Hung, Pi-Han Lin, Shu-Fang Chang, Ching-Yao Yang, Sui-Yuan Chang, Shan-Chwen Chang, Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan Journal of Antimicrobial Chemotherapy. ,vol. 60, pp. 599- 604 ,(2007) , 10.1093/JAC/DKM243